List view / Grid view
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring…
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
